Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 5, 2011, Pages 197-203

  Astarita, Giuseppe ^a,c,d   Piomelli, Daniele ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

DHA; Docosahexaenoic acid; Lipid metabolism; Liver brain axis; Omega 3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; OMEGA 3 FATTY ACID;

AGING; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; FAT INTAKE; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; LIPID ANALYSIS; LIPID BRAIN LEVEL; LIPID COMPOSITION; LIPID STORAGE; LIPIDOMICS; LIPOGENESIS; MENTAL DISEASE; METABOLIC REGULATION; NONHUMAN; PEROXISOME; PRIORITY JOURNAL;

17-HYDROXYSTEROID DEHYDROGENASES; ALZHEIMER DISEASE; DOCOSAHEXAENOIC ACIDS; HUMANS; HYDRO-LYASES; LIPID METABOLISM; LIVER; ORGAN SPECIFICITY; PEROXISOMES;

EID: 80053601290     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.021     Document Type: Article

References (138)

1. Astarita G., Jung K., Berchtold N., et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoSOne 2010, 5(9):e12538.
2. M.Prince, J. Jackson A.s.D. International, (Ed.), London, 2009.
3. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 2004, 351(1):56-67.
4. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8(7):499-509.
5. Beach T.G., Wilson J.R., Sue L.I., et al. Circle of Willis atherosclerosis: Association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta. Neuropathol. 2007, 113(1):13-21.
6. Cunnane S.C., Plourde M., Pifferi F., Begin M., Feart C., Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog. Lipid. Res. 2009.
7. Lim G.P., Calon F., Morihara T., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25(12):3032-3040.
8. Calon F., Lim G.P., Yang F., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43(5):633-645.
9. Suzuki H., Morikawa Y., Takahashi H. Effect of DHA oil supplementation on intelligence and visual acuity in the elderly. World Rev. Nutr. Diet. 2001, 88:68-71.
10. Morris M.C., Evans D.A., Bienias J.L., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60(7):940-946.
11. Kalmijn S., van Boxtel M.P., Ocke M., Verschuren W.M., Kromhout D., Launer L.J. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004, 62(2):275-280.
12. Horrocks L.A., Farooqui A.A. Docosahexaenoic acid in the diet: Its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 2004, 70(4):361-372.
13. Green K.N., Martinez-Coria H., Khashwji H., et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 2007, 27(16):4385-4395.
14. Barberger-Gateau P., Raffaitin C., Letenneur L., et al. Dietary patterns and risk of dementia: The Three-City cohort study. Neurology 2007, 69(20):1921-1930.
15. Conquer J.A., Tierney M.C., Zecevic J., Bettger W.J., Fisher R.H. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000, 35(12):1305-1312.
16. Tully A.M., Roche H.M., Doyle R., et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: A case-control study. Br. J. Nutr. 2003, 89(4):483-489.
17. Young G., Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod. Nutr. Dev. 2005, 45(1):1-28.
18. Umhau J.C., Zhou W., Carson R.E., et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J. Lipid. Res. 2009, 50(7):1259-1268.
19. Rapoport S.I., Igarashi M. Can the rat liver maintain normal brain DHA metabolism in the absence of dietary DHA?. Prostaglandins Leukot Essent Fatty Acids 2009, 81(2-3):119-123.
20. Scott B., Bazan N. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc. Natl. Acad. Sci. USA 1989, 86(8):2903-2907.
21. Salem N., Litman B., Kim H.Y., Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001, 36(9):945-959.
22. Kim H.Y. Novel Metabolism of Docosahexaenoic Acid in Neural Cells. J. Biol. Chem. 2007, 282(26):18661.
23. Stubbs C.D., Smith A.D. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim. Biophys. Acta. 1984, 779(1):89-137.
24. Martin R.E., Bazan N.G. Changing fatty acid content of growth cone lipids prior to synaptogenesis. J. Neurochem. 1992, 59(1):318-325.
25. Breckenridge W.C., Gombos G., Morgan I.G. The lipid composition of adult rat brain synaptosomal plasma membranes. Biochim. Biophys. Acta. 1972, 266(3):695-707.
26. Grossfield A., Feller S.E., Pitman M.C. A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc. Natl. Acad. Sci. USA 2006, 103(13):4888-4893.
27. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006, 75(4-5):259-269.
28. Stillwell W., Shaikh S.R., Zerouga M., Siddiqui R., Wassall S.R. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod, Nutr, Dev. 2005, 45(5):559-579.
29. Farooqui A.A., Horrocks L.A. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 2006, 12(3):245-260.
30. Marszalek J.R., Lodish H.F. Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish are good for you. Annu. Rev. Cell Dev. Biol. 2005, 21:633-657.
31. de Urquiza A.M., Liu S., Sjoberg M., et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000, 290(5499):2140-2144.
32. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. J. Biol. Chem. 2003, 278(17):14677-14687.
33. Schwab J.M., Chiang N., Arita M., Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447(7146):869-874.
34. Lukiw W.J., Cui J.G., Marcheselli V.L., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 115(10):2774-2783.
35. Mukherjee P.K., Marcheselli V.L., Serhan C.N., Bazan N.G. Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 2004, 101(22):8491-8496.
36. Fam S.S., Murphey L.J., Terry E.S., et al. Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem. 2002, 277(39):36076-36084.
37. Favrelere S., Stadelmann-Ingrand S., Huguet F., et al. Age-related changes in ethanolamine glycerophospholipid fatty acid levels in rat frontal cortex and hippocampus. Neurobiol. Aging. 2000, 21(5):653-660.
38. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 1998, 23(1):81-88.
39. Bazan N.G. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care. 2007, 10(2):136-141.
40. Montuschi P., Barnes P.J., Roberts L.J. Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004, 18(15):1791-1800.
41. Milionis H.J., Florentin M., Giannopoulos S. Metabolic syndrome and Alzheimer's disease: A link to a vascular hypothesis?. CNS Spectr 2008, 13(7):606-613.
42. de la Torre J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet. Neurol. 2004, 3(3):184-190.
43. Innis S.M. Dietary omega 3 fatty acids and the developing brain. Brain. Res. 2008, 1237:35-43.
44. Crawford M.A., Bazinet R.P., Sinclair A.J. Fat intake and CNS functioning: Ageing and disease. Ann. Nutr. Metab. 2009, 55(1-3):202-228.
45. Lukiw W., Bazan N. Docosahexaenoic acid and the aging brain. J. Nutr. 2008, 138(12):2510.
46. Florent S., Malaplate-Armand C., Youssef I., et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J. Neurochem. 2006, 96(2):385-395.
47. Brooksbank B.W., Martinez M. Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease. Mol. Chem. Neuropathol. 1989, 11(3):157-185.
48. Soderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26(6):421-425.
49. Guan Z., Wang Y., Cairns N.J., Lantos P.L., Dallner G., Sindelar P.J. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 1999, 58(7):740-747.
50. Skinner E.R., Watt C., Besson J.A., Best P.V. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 1993, 116(Pt3):717-725.
51. Corrigan F.M., Horrobin D.F., Skinner E.R., Besson J.A., Cooper M.B. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int. J. Biochem. Cell Biol. 1998, 30(2):197-207.
52. Fraser T., Tayler H., Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem. Res. 2009, 35(3):503-513.
53. Kwee I.L., Nakada T., Ellis W.G. Elevation in relative levels of brain membrane unsaturated fatty acids in Alzheimer's disease: High resolution proton spectroscopic studies of membrane lipid extracts. Magn. Reson. Med. 1991, 21(1):49-54.
54. Burdge G., Calder P. Conversion of\ alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reproduction, Nutrition, Development 2005, 45(5):581-597.
55. Rapoport S., Rao J., Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent. Fatty Acids 2007, 77(5-6):251-261.
56. Voss A., Reinhart M., Sankarappa S., Sprecher H. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J. Biol. Chem. 1991, 266(30):19995-20000.
57. Sprecher H., Luthria D.L., Mohammed B.S., Baykousheva S.P. Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids. J. Lipid. Res. 1995, 36(12):2471-2477.
58. Moore S.A., Hurt E., Yoder E., Sprecher H., Spector A.A. Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. J. Lipid. Res. 1995, 36(11):2433-2443.
59. Su H.M., Moser A.B., Moser H.W., Watkins P.A. Peroxisomal straight-chain Acyl-CoA oxidase and d-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis. J. Biol. Chem. 2001, 276(41):38115-38120.
60. Freemantle E., Vandal M., Tremblay-Mercier J., et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot Essent Fatty Acids 2006, 75(3):213-220.
61. Albert C.M., Oh K., Whang W., et al. Dietary alpha-linolenic acid intake and risk of sudden cardiac death and coronary heart disease. Circulation 2005, 112(21):3232-3238.
62. Denomme J., Stark K.D., Holub B.J. Directly quantitated dietary (n-3) fatty acid intakes of pregnant Canadian women are lower than current dietary recommendations. J. Nutr. 2005, 135(2):206-211.
63. Brenna J.T. Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man. Curr. Opin. Clin. Nutr. Metab. Care 2002, 5(2):127-132.
64. Burdge G.C., Wootton S.A. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br. J. Nutr. 2002, 88(4):411-420.
65. Sinclair A.J., Attar-Bashi N.M., Li D. What is the role of alpha-linolenic acid for mammals?. Lipids. 2002, 37(12):1113-1123.
66. Hussein N., Ah-Sing E., Wilkinson P., Leach C., Griffin B.A., Millward D.J. Long-chain conversion of [13C]linoleic acid and alpha-linolenic acid in response to marked changes in their dietary intake in men. J. Lipid. Res. 2005, 46(2):269-280.
67. Plourde M., Cunnane S.C. Extremely limited synthesis of long chain polyunsaturates in adults: Implications for their dietary essentiality and use as supplements. Appl. Physiol. Nutr. Metab. 2007, 32(4):619-634.
68. Astarita G., Ahmed F., Piomelli D. Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. Methods. Mol. Biol. 2009, 579:201-219.
69. Astarita G., Piomelli D. Lipidomic analysis of endocannabinoid metabolism in biological samples. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2009.
70. Bazan N.G. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 2006, 29(5):263-271.
71. Muldoon, M.F., Ryan, C.M., Sheu, L., Yao, J.K., Conklin, S.M., Manuck, S.B. Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood. J. Nutr. 140(4) 848-853.
72. Corrigan F.M., Van Rhijn A.G., Ijomah G., et al. Tin and fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids. 1991, 43(4):229-238.
73. Beydoun M.A., Kaufman J.S., Satia J.A., Rosamond W., Folsom A.R. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: The Atherosclerosis Risk in Communities Study. Am. J. Clin. Nutr. 2007, 85(4):1103-1111.
74. Schaefer E.J., Bongard V., Beiser A.S., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch. Neurol. 2006, 63(11):1545-1550.
75. Cherubini A., Andres-Lacueva C., Martin A., et al. Low plasma N-3 fatty acids and dementia in older persons: the InCHIANTI study. J. Gerontol. A Biol. Sci. Med. Sci. 2007, 62(10):1120-1126.
76. Goodenowe D.B., Cook L.L., Liu J., et al. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J. Lipid. Res. 2007, 48(11):2485-2498.
77. Hooijmans C., Kiliaan A. Fatty acids, lipid metabolism and Alzheimer pathology. Eur. J. Pharmacol. 2008, 585(1):176-196.
78. Sanchez-Mejia R., Newman J., Toh S., et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 2008, 11(11):1311-1318.
79. Britschgi M., Wyss-Coray T. Systemic and acquired immune responses in Alzheimer's disease. Int. Rev. Neurobiol. 2007, 82:205-233.
80. Wyss-Coray T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response?. Nat. Med. 2006, 12(9):1005-1015.
81. Steinman L. Elaborate interactions between the immune and nervous systems. Nat. Immunol. 2004, 5:575-581.
82. SCOTT R. Extraneuronal manifestations of Alzheimer's disease. J. Am. Geriatr. Soc. 1993, 41(3):268-276.
83. Blass J., Zemcov A. Alzheimer's disease. A metabolic systems degeneration?. Neurochem. Pathol. 1984, 2(2):103-114.
84. Ghiso J., Shayo M., Calero M., et al. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J. Biol. Chem. 2004, 279(44):45897-45908.
85. Marques M.A., Kulstad J.J., Savard C.E., et al. Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system. J. Alzheimers Dis. 2009, 16(2):325-329.
86. Roher A.E., Esh C.L., Kokjohn T.A., et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009, 5(1):18-29.
87. Jiang L.L., Kurosawa T., Sato M., Suzuki Y., Hashimoto T. Physiological role of D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein. J. Biochem. 1997, 121(3):506-513.
88. Martinez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain. Res. 1992, 583(1-2):171-182.
89. Martinez M. Severe deficiency of docosahexaenoic acid in peroxisomal disorders: A defect of delta 4 desaturation?. Neurology 1990, 40(8):1292-1298.
90. Youssef J., Badr M. Biology of senescent liver peroxisomes: Role in hepatocellular aging and disease. Environ Health Perspect 1999, 107(10):791-797.
91. Haining J.L., Legan J.S. Catalase turnover in rat liver and kidney as a function of age. Exp. Gerontol. 1973, 8(2):85-91.
92. Huang T.L., Zandi P.P., Tucker K.L., et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005, 65(9):1409-1414.
93. Freund-Levi Y., Eriksdotter-Jonhagen M., Cederholm T., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 2006, 63(10):1402-1408.
94. Plourde M., Vohl M.C., Vandal M., Couture P., Lemieux S., Cunnane S.C. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. Br. J. Nutr. 2009, 102(8):1121-1124.
95. Lewis M., Howdle P.D. The neurology of liver failure. QJM 2003, 96(9):623-633.
96. Collie A. Cognition in liver disease. Liver Int. 2005, 25(1):1-8.
97. Yilmaz Y., Ozdogan O. Liver disease as a risk factor for cognitive decline and dementia: An under-recognized issue. Hepatology 2009, 49(2):698. author reply.
98. Pawlosky R.J., Salem N. Alcohol consumption in rhesus monkeys depletes tissues of polyunsaturated fatty acids and alters essential fatty acid metabolism. Alcohol Clin. Exp. Res. 1999, 23(2):311-317.
99. Frye M.A., Salloum I.M. Bipolar disorder and comorbid alcoholism: Prevalence rate and treatment considerations. Bipolar. Disord. 2006, 8(6):677-685.
100. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond). 2004, 106(6):635-643.
101. Allard J.P., Aghdassi E., Mohammed S., et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional study. J. Hepatol. 2008, 48(2):300-307.
102. Spadaro L., Magliocco O., Spampinato D., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 2008, 40(3):194-199.
103. Capanni M., Calella F., Biagini M.R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol. Ther. 2006, 23(8):1143-1151.
104. Janssen A., Gressens P., Grabenbauer M., et al. Neuronal migration depends on intact peroxisomal function in brain and in extraneuronal tissues. J. Neurosci. 2003, 23(30):9732-9741.
105. Perichon R., Bourre J.M. Peroxisomal beta-oxidation activity and catalase activity during development and aging in mouse liver. Biochimie 1995, 77(4):288-293.
106. Masters C.J., Crane D.I. On the role of the peroxisome in ontogeny, ageing and degenerative disease. Mech. Ageing. Dev. 1995, 80(2):69-83.
107. Martinez M. Docosahexaenoic acid therapy in docosahexaenoic acid-deficient patients with disorders of peroxisomal biogenesis. Lipids. 1996, 31(Suppl.):S145-S152.
108. Boston P.F., Bennett A., Horrobin D.F., Bennett C.N. Ethyl-EPA in Alzheimer's disease-A pilot study. Prostaglandins Leukot Essent Fatty Acids 2004, 71(5):341-346.
109. Zoeller R.A., Raetz C.R. Isolation of animal cell mutants deficient in plasmalogen biosynthesis and peroxisome assembly. Proc. Natl. Acad. Sci. USA 1986, 83(14):5170-5174.
110. Burdge G.C., Finnegan Y.E., Minihane A.M., Williams C.M., Wootton S.A. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men. Br. J. Nutr. 2003, 90(2):311-321.
111. *. Br. J. Nutr. 2002, 88(4):355-363.
112. McNamara R.K., Liu Y., Jandacek R., Rider T., Tso P. The aging human orbitofrontal cortex: Decreasing polyunsaturated fatty acid composition and associated increases in lipogenic gene expression and stearoyl-CoA desaturase activity. Prostaglandins Leukot Essent Fatty Acids 2008, 78(4-5):293-304.
113. Saiz J.L., Lopez-Zumel C., Monterroso B., et al. Characterization of Ejl, the cell-wall amidase coded by the pneumococcal bacteriophage Ej-1. Protein Sci. 2002, 11(7):1788-1799.
114. Ulmann L., Mimouni V., Roux S., Porsolt R., Poisson J.P. Brain and hippocampus fatty acid composition in phospholipid classes of aged-relative cognitive deficit rats. Prostaglandins Leukot Essent Fatty Acids 2001, 64(3):189-195.
115. K. Yurko-Mauro, D. McCarthy, D. Rom, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement [Epub ahead of print].
116. McNamara R.K., Jandacek R., Rider T., et al. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 2008, 160(3):285-299.
117. McNamara R.K., Jandacek R., Rider T., et al. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: Gender differences and partial normalization with antipsychotic medications. Schizophr Res. 2007, 91(1-3):37-50.
118. McNamara R.K., Hahn C.G., Jandacek R., et al. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol. Psychiatry 2007, 62(1):17-24.
119. Sarri K.O., Linardakis M., Tzanakis N., Kafatos A.G. Adipose DHA inversely associated with depression as measured by the Beck Depression Inventory. Prostaglandins Leukot Essent Fatty Acids 2008, 78(2):117-122.
120. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry. 1991, 30(8):795-805.
121. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res. 2000, 42(1):7-17.
122. Hibbeln J.R. Depression, suicide and deficiencies of omega-3 essential fatty acids in modern diets. World Rev. Nutr. Diet. 2009, 99:17-30.
123. Amminger G.P., Berger G.E., Schafer M.R., Klier C., Friedrich M.H., Feucht M. Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry 2007, 61(4):551-553.
124. Conklin S.M., Manuck S.B., Yao J.K., Flory J.D., Hibbeln J.R., Muldoon M.F. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med. 2007, 69(9):932-934.
125. Bourre J.M. Dietary omega-3 Fatty acids and psychiatry: mood, behaviour, stress, depression, dementia and aging. J. Nutr. Health. Aging. 2005, 9(1):31-38.
126. Keck P.E., Mintz J., McElroy S.L., et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol. Psychiatry 2006, 60(9):1020-1022.
127. VanItallie T.B. Subsyndromal depression in the elderly: Underdiagnosed and undertreated. Metabolism 2005, 54(5 Suppl 1):39-44.
128. Geerlings M.I., den Heijer T., Koudstaal P.J., Hofman A., Breteler M.M. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008, 70(15):1258-1264.
129. Wilson R.S., Arnold S.E., Beck T.L., Bienias J.L., Bennett D.A. Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch. Gen. Psychiatry 2008, 65(4):439-445.
130. Nasrallah H.A. Neurodevelopmental aspects of bipolar affective disorder. Biol. Psychiatry 1991, 29(1):1-2.
131. Taylor M.A. Are schizophrenia and affective disorder related? A selective literature review. Am. J. Psychiatry 1992, 149(1):22-32.
132. Elkis H., Friedman L., Wise A., Meltzer H.Y. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch. Gen. Psychiatry 1995, 52(9):735-746.
133. Najt P., Nicoletti M., Chen H.H., et al. Anatomical measurements of the orbitofrontal cortex in child and adolescent patients with bipolar disorder. Neurosci Lett. 2007, 413(3):183-186.
134. Bremner J.D., Vythilingam M., Vermetten E., et al. Reduced volume of orbitofrontal cortex in major depression. Biol. Psychiatry. 2002, 51(4):273-279.
135. Conklin S.M., Gianaros P.J., Brown S.M., et al. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci. Lett. 2007, 421(3):209-212.
136. Ahmad A., Moriguchi T., Salem N. Decrease in neuron size in docosahexaenoic acid-deficient brain. Pediatr. Neurol. 2002, 26(3):210-218.
137. Noguer M.T., Martinez M. Visual follow-up in peroxisomal-disorder patients treated with docosahexaenoic acid ethyl ester. Invest Ophthalmol Vis. Sci. 2009, 51(4):2277-2285.
138. Burke P.A., Ling P.R., Forse R.A., Lewis D.W., Jenkins R., Bistrian B.R. Sites of conditional essential fatty acid deficiency in end stage liver disease. J. Parenter Enteral Nutr. 2001, 25(4):188-193.